The outlook for Teva Pharmaceutical Industries Ltd. in 2019 is straightforward. It will be a year of more cost-cutting and continued focus as the company looks to stabilize financials and reduce its debt. Teva hopes 2019 will be the year it bottoms out before returning to growth in 2020.
The company is not looking to jumpstart the top line with any business development, as CEO Kare Schultz made clear...